Posted by AGORACOM-JC
at 3:27 PM on Thursday, November 14th, 2019
SPONSOR: BetterU Education Corp.
aims to provide access to quality education from around the world.
The company plans to bridge the prevailing gap in the education and job
industry and enhance the lives of its prospective learners by developing
an integrated ecosystem. Click here for more information.
Samsung-Backed TagHive Enters India To Digitise Public Schools With Edtech Device And Platform
TagHive has launched Class Sathi in two Madhya Pradesh districts
The startup was a part of Samsung’s C-lab incubator programme
TagHive aims to bring affordable digital learning to primary schools in rural India
In the Indian context, the education infrastructure and quality of
learning has always come under scrutiny, especially due to concerns of
outdated syllabi and teaching methods at the primary level in public
schools.
Most edtech startups in India are looking to solve this by bringing
learning to the mobile phone or PC, but that’s not always possible at
schools in smaller towns and villages, which do not have the wherewithal
to implement such high-tech solutions. That’s what TagHive is looking
to overcome with its affordable edtech platform (device and software)
for the Indian public and primary school market.
Suwon, South Korea-based TagHive has launched its flagship product
Class Saathi in two districts of Madhya Pradesh. Tying up with the state
government, TagHive’s Class Saathi mobile clicker solution and the
companion app will be available across 13 schools in its two districts.
Founded in 2017 by IIT and Harvard alumni, Pankaj Agarwal, the
startup for his innovation in the education segment has received funds
from Samsung Ventures and Enlight Ventures. The startup was also
incubated by Samsung’s internal C-Lab programme after the South Korean
chaebol discovered Agarwal’s idea during his stint at the company.
Speaking to Inc42, the founder said that Samsung C-Lab supported
TagHive with the necessary resources such as funding, workspace,
technical support and culture-building through the incubation programme.
“After 15 months of working on my idea at Samsung, it was chosen to be
spun off as an independent company, TagHive. Samsung Ventures has put in
seed capital of over INR 2.5 Cr,†Agarwal said.
The AI-powered classroom engagement solution Class Saathi aims to
make tech-based learning accessible and affordable for schools in rural
India with little or no infrastructural investments. The startup also
aims to increase student participation and learning outcomes, while at
the same time supporting and motivating teachers to improve their
teaching methodology.
TagHive doesn’t just limit itself to teachers and students but also
involves another key stakeholder in the education chain — the child’s
parents. Agarwal said that this helps keep everyone in the loop about
the student’s progress.
Posted by AGORACOM-JC
at 1:55 PM on Thursday, November 14th, 2019
SPONSOR:
Why Empower Clinics
A leading owner/operator of physician staffed health and pain management clinics
Patient database of over 165,000 patientsÂ
Platform generating $4MM USD in revenue annually (2019)
Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
Launching CBD extraction facility
First extraction system capacity = 6,000 Kg per year.
The case for treating PTSD with cannabis
Previous research has linked cannabis use with poorer mental health in PTSD patients, but it’s unclear whether cannabis exacerbates PTSD symptoms, or if patients with worse symptoms are simply self-medicating more.
As epidemiologists and substance use researchers, we have been
exploring the relationship between cannabis and PTSD using readily
available Statistics Canada mental health data.
In a recent study, published in the Journal of Psychopharmacology,
we found that PTSD increased the risk of major depressive episodes
among Canadians who didn’t use cannabis by roughly seven times, and
suicidal ideation by roughly five times. But, among Canadians who did
use cannabis, PTSD was not statistically associated with either outcome.
How cannabis works in the body
Substance use, including cannabis use,
is common among trauma survivors. It’s easy to write off the drug as
just a tool to briefly escape negative feelings, at the risk of
worsening longer-term symptoms. However, the relationship between
cannabis and PTSD is more complex than it appears on the surface.
Certain components of the cannabis plant,
including the well-known molecules tetrahydrocannabinol (THC, the
component of cannabis that produces the high) and cannabidiol (CBD, the
component of cannabis that won’t get you high, but has potential for
treating epilepsy, inflammation, nausea and anxiety) are also cannabinoids because of their structural similarity to endogenous cannabinoids.
Research is still uncovering if and how cannabis works within the
body to affect the course of PTSD. Brain imaging research suggests that
patients with PTSD have an abundance of cannabinoid receptors but produce few endogenous cannabinoids
to lock into them, meaning that supplementing the body with plant-based
cannabinoids like THC might help some brain processes function as
normal.
Reduced depression and suicide
Roughly one in four individuals with PTSD in the Statistics Canada
survey data that we analyzed used cannabis, compared to about one in
nine in the general population.
In our study, we used statistical models to quantify the relationship
between having PTSD and recently experiencing a major depressive
episode or suicidal ideation. We hypothesized that if cannabis helped
mitigate symptoms of PTSD, we’d see a much weaker association between
PTSD and these indicators of mental distress in the cannabis-using
population.
Indeed, exploring the associations in this way while controlling for
other factors (such as sex, age, income, other substance use, other
mental health problems) supported our hypothesis.
In a follow-up analysis of the 420 individuals in the sample who had
PTSD, we categorised cannabis use into “no use,†“low-risk use†and
“high-risk use†(meaning that they screened positive for cannabis abuse
or dependence).
We found that low-risk cannabis users were actually less likely than
non-users to develop a major depressive episode or to be suicidal,
though there was a trend towards increased risk of both outcomes for the
high-risk users.
A promising new signal
People with PTSD are more likely to experience depression and
suicidal ideation. However, our findings suggested that these indicators
of mental health were improved when they were engaging in lower-risk
cannabis use.
Our study has a number of limitations that prevent us from being able
to understand whether cannabis is what’s causing the reduced
association between PTSD, depression and suicide.
For example, our data captures information covering participants’
experiences from the previous year, meaning we can’t actually decipher
what came first: the cannabis use, the PTSD or the major psychological
episodes.
We didn’t have detailed information about how participants used
cannabis: for example, the type and dose of cannabis they used, how
often they used it or how they consumed it. These details will be
crucial to future research in this area.
Our study’s strength comes from its ability to describe patterns of
PTSD symptoms and cannabis use in a large sample that’s considered to be
representative of the Canadian population. Although our findings
suggest that cannabis could be of possible therapeutic use in the
treatment of PTSD, cannabis use is not without risks, including the
development of cannabis use disorder.
We’ve uncovered a promising new signal on the potential of
cannabis-based therapies, but we look forward to much work ahead in
understanding how they might fit into PTSD and mental health treatment
more broadly.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – The case for treating #PTSD with #cannabis $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 12:59 PM on Thursday, November 14th, 2019
SPONSOR: New Age Metals Inc.
The company’s Lithium Division has already made significant
acquisitions in Canada and the USA. The company also owns one of North
America’s largest primary platinum group metals deposit in Sudbury,
Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq
Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces
in the Inferred. Learn More.
Sales Revenue of Palladium to Soar in the Near Future Owing to Growing Consumer Adoption
Global market for palladium is likely to experience
significant growth with declining demand for metals and increasing
demand for recycling metals, leading to palladium demand outstripping
the supply.
In addition, changing prospects of investments in palladium have also contributed to the growth of the market
Palladium
is a lustrous silvery-white rare metal used in a diverse range of
applications. The metal with other elements such as osmium, iridium,
ruthenium, rhodium, and platinum are referred to as Platinum Group
Metals (PGM). Palladium is majorly consumed in the automotive industry
as catalytic converters, manufacturing of electronics and jewelry, as
well as chemical and dental applications. Palladium is sourced from two
major sources, viz., mine production and recycling.
The global market for palladium is likely to experience significant
growth with declining demand for metals and increasing demand for
recycling metals, leading to palladium demand outstripping the supply.
In addition, changing prospects of investments in palladium have also
contributed to the growth of the market. Several new palladium
exchange-traded funds by companies such as Absa Capital in South
Africa are expected to create a significant boost for the palladium
market.
Growing demand for palladium in catalytic converters in the
automotive industry in vehicles exhausts are one of the major growth
factors driving the palladium market. Demand for the metal from other
sectors such as jewelry and industrial are also anticipated to
contribute to the growth of the market. However, rising prices of
palladium owing to supply issues in South Africa and declining state
stockpiles in Russia are expected to hamper the growth of the market.
North America was the largest consumer for palladium, followed by China
owing to the presence of the vast automotive industry in the region.
Future market growth is expected to be from Asia Pacific with the
growing industrial activities in emerging economies such as India. These
factors are expected to provide new opportunities for the growth of the
market.
Posted by AGORACOM-JC
at 8:23 AM on Thursday, November 14th, 2019
5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.
Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.
VANCOUVER, Nov. 14, 2019 - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., has filed today its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30th, 2019 and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.
“Our focus on operational excellence and cost controls are key
contributors to strong year-over-year growth numbers and the reduction
in direct clinic expense, as we continue to serve the 165,000 patients
in our database,” said Steven McAuley, Empowers Chairman
& CEO. “The Company is beginning to fulfill its promise of vertical
integration with the build-out of the extraction and production center
in Portland, OR plus with an increased focus on our
proprietary CBD product lines and diversified clinic revenues, the
Company has a clear path of growth and profitability going forward.”
Q3 2019 Highlights
5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.
Net loss of $504,531, compared to $378,657
for Q3 2018, which was primarily driven by increased revenues and fair
value adjustments offset by net increased in operating expenses related
to the operations of Sun Valley.
Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.
Cash at September 30, 2019 of $178,578, compared to $157,668 at December 31, 2018, which was primarily driven by debt and equity financings during the nine months ended September 30, 2019
and partially offset by cash used in operations, the cash investment in
Sun Valley and cash investment in Sun Valley Health Franchise launch.
Highlights
Strategic redirection: The Company has been
re-positioning its overall strategy to become a vertically integrated
health and wellness brand that connects to its 165,000 patients using a
data driven focus to improve patients’ lives with products, technology
and health systems.
Experienced and Seasoned Board of Directors: The Company Board of Directors includes its CEO Steven McAuley, Dustin Klein,
the Co-Founder of Sun Valley Clinics and the SVP, Business Development
and Andrejs Bunkse, owner and practicing attorney of Rain Legal and
Counsel to numerous cannabis enterprises in the U.S. and Canada.
Strategic Development: The Company has opened its first hemp-derived CBD extraction facility in greater Portland, Oregon
with the first extraction system expected to have the capacity to
produce 6,000 kg of extracted product per year. The Company took
possession of the new extraction facility June 1st, 2019
and has been awarded it’s hemp-handlers licence from the Oregon
Department of Agriculture, allowing the Company to enter the next phase
of build-out and full operations in 2019. The Company expects
preliminary production of its Sollievo CBD line to take place in the
extraction center in 4Q 2019.
Strategic Partnership: The Company has entered into a
Letter of Intent (“LOI”) to form a Joint Venture Partnership (“JV”) with
Heritage Cannabis Holdings Corp (CSE: CANN) (“Heritage”). Terms of the
LOI have Empower and Heritage each with a 50% ownership of the JV.
Heritage will install extraction units and related downstream extraction
equipment inside Empower’s existing licenced hemp processing facility
in Sandy, Oregon. Once operational, the JV will begin
producing proprietary branded products for Empower’s clinics and third
party partners for distribution in the United States.
2019 Outlook and Catalysts
Enhanced Corporate Governance: The Company has prioritized corporate governance practices under the leadership of its Board of Directors and Chairman Steven McAuley, to ensure financial and accounting controls operate at the highest of standards.
Improved Capital Markets Profile: Empower is
diversifying its business model to become a vertically integrated
operator in the global cannabis sector with a focus on patient care, CBD
product distribution, research & development and CBD product
extraction. The Company believes this will appeal to a broader base of
shareholders and investors and provide greater access to capital and
improved trading liquidity.
Increased Patient Access: With a rapidly expanding
company-owned clinic network and significant expansion opportunity
through the Sun Valley Health franchise model, Empower anticipates it
will grow its total patient list substantially in the years ahead. This
is expected to provide greater opportunity for treatment analysis using
artificial intelligence (AI), through progressive initiatives that
include adding the Endocanna DNA test kit to the Company product &
service offering in clinics and online. Ensuring the Company is a leader
in understanding the efficacy of cannabis-related treatment options is
an imperative.
Focus on CBD Product Sales: The Company has launched
its online store to sell its lines of hemp-derived CBD based products
and premium health & wellness supplements. Customers can purchase
products, including CBD lotions, tinctures, spectrum oils, capsules,
lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract
drops and pet-elixir hemp extract drops. Patients and customers will be
able to access Sun Valley Health customer service, home delivery and
e-commerce platforms.
Market Leading Technology: Empower utilizes
market-leading patient electronic management and POS system that is
HIPAA compliant and provides deep insight to patient care. The Company
supports remote patients using its tele-medicine portal, enabling
patients who do not live near one of its clinic locations, or are
disabled or unable to come to a location, to still benefit from a doctor
consultation.
New Modalities and Services: The Company has launched
new physician based modalities and services into the Sun Valley Health
clinics and has commenced booking appointments and providing the new
services. Each of these services provides the opportunity for increased
patient retention, higher revenue per patient visit and increased
patient visits per year. The new services include:
Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
Spectracell Micronutrient Test & Physician Consultation/Action Plan
Launches Nationwide Franchise: The Company has launched
its nationwide franchise program under the Sun Valley Health brand to
dramatically grow our clinic & store footprint increasing direct
access to patients and to sell hemp-derived CBD products and premium
wellness products directly to our customers and online at our new
e-commerce store at www.sunvalleyhealth.com
Financial Summary
$, except patient visits
Three months ended
September 30,
Nine months ended
September 30,
2019
2018
2019
2018
Patient visits
5,807
1,864
11,304
6,293
Clinic revenues
663,003
279,850
1,406,872
894,477
Direct clinic expenses
(55,397)
(88,956)
(177,560)
(301,392)
Loss from operations
(843,897)
(405,048)
(2,547,276)
(3,716,474)
Net loss
(504,531)
(378,657)
(2,359,579)
(5,132,848)
Net loss per share
(0.00)
(0.01)
(0.02)
(0.09)
Financial Performance
Clinic revenues for Q3 2019 were $663,003, compared to Q3 2018 revenues of $279,850. This increase over the prior year is attributable to the acquisition of Sun Valley Clinics.
Direct clinic expenses for Q3 2019 were $55,397, compared to Q3 2018 direct clinic expenses of $88,956.
These expenses declined despite the increase in revenues due to
improved operational controls to align labor cost with direct patient
consultations. The Company employs a diverse mix of physicians and
practitioners.
Net loss from operations for Q3 2019 was $843,897, compared to Q3 2018 net loss of $405,048.
This increase in loss over prior year is primarily attributable
operating expenses increasing due to timing of recognition of the
expense associated with non-cash share-based awards to management.
Net loss for Q3 2019 was $504,531, respectively, compared to Q3 2018 net loss of $378,657.
This increase over prior year is primarily attributable to the increase
in operating expenses as noted above, which was partially offset by
gains on change in fair value of the conversion option of convertible
debentures and warrants.
During Q3 2019, the Company used $1,819,670 in cash from operations after changes in non-cash working capital. The Company invested $629,636 for the acquisition of Sun Valley Clinics and raised $2,470,216 via proceeds from various issuances of shares, convertible debentures and notes.
Please refer to the Company’s unaudited condensed interim
consolidated financial statements, related notes and accompanying
management discussion and analysis for a full review of the operations.
ABOUT EMPOWER
Empower is a vertically integrated and growth-oriented CBD life
sciences company, and a multi-state operator of medical health &
wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States.
As a CBD product manufacturer under the Sollievo brand, the Company
distributes its lines through clinics, online and through retail
partners. Extraction operations are currently being developed in the
Company’s new extraction facility in Oregon.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws. All
statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release. Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to open a hemp-based CBD
extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the terms of the proposed acquisitions and partnerships; the
effectiveness of the extraction technology; the expected benefits for
Empower’s patient base and customers; the benefits of CBD based
products; the effect of the approval of the Farm Bill; the growth of the
Company’s patient list and that the Company will be positioned to be a
market-leading service provider for complex patient requirements in 2019
and beyond. Such statements are only projections, are based on
assumptions known to management at this time, and are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including; that the Company may not open a
hemp-based CBD extraction facility; that the hemp-based CBD extraction
facility may not be fully operational in 2019 if at all; that
legislative changes may have an adverse effect on the Company’s business
and product development; that the Company may not be able to obtain
adequate financing to pursue its business plan; general business,
economic, competitive, political and social uncertainties; failure to
obtain any necessary approvals in connection with the proposed
acquisitions and partnerships; and other factors beyond the Company’s
control. No assurance can be given that any of the events anticipated by
the forward-looking statements will occur or, if they do occur, what
benefits the Company will obtain from them. Readers are cautioned not to
place undue reliance on the forward-looking statements in this release,
which are qualified in their entirety by these cautionary statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements in this release, whether as a result of new information,
future events or otherwise, except as expressly required by applicable
laws.
Posted by AGORACOM-JC
at 7:17 AM on Thursday, November 14th, 2019
50,000 plus tweets we analyzed in one day, more that 30 accounts were suspicious in nature and using the issue to promote a divisive agenda.
A number of the accounts identified were also active in the #ELXN43 campaign buzz on social media
“This project further demonstrates how important it is to have tools to identify fake news sources so government, corporations and high profile individuals can control the narrative around their issues and brands,†says Marshall Gunter, CEO of the Company.
TORONTO, Nov. 14, 2019 — Datametrex AI Limited (the “Company†or “Datametrexâ€) (TSXV: DM, FSE: D4G) yesterday shared the results of its fake news filter on the Canadian Federal Elections ( #ELXN43 ) in coordination with our client, Defence Research and Development Canada (DRDC). Now that the tool has been built and delivered, the Company is now able to further commercialize the solution and offer it to government and enterprise clients alike.Â
Out of interest, we decided to turn the filter on the recent scandal
involving hockey commentator Don Cherry to see if known propaganda
accounts and BOTs were active in the conversations and trying to use it
as a wedge to further divide public opinion in Canada. We were not
surprised to learn that of the 50,000 plus tweets we analyzed in one
day, more that 30 accounts were suspicious in nature and using the issue
to promote a divisive agenda. A number of the accounts identified were
also active in the #ELXN43 campaign buzz on social media.
As with the project we completed for DRDC, we used our NexaNarrative tool,
for narrative tracking, disinformation detection, and publisher
classification. Building on our previous fake news detection work,
NexaNarrative provides narrative identification and growth tracking
software that allows analysts to track the spread of disinformation
online and to engage this disinformation using the BEND doctrine of information warfare currently in use by Canada and most other NATO countries.
“This project further demonstrates how important it is to have tools
to identify fake news sources so government, corporations and high
profile individuals can control the narrative around their issues and
brands,†says Marshall Gunter, CEO of the Company.
For more information on this project or to learn how Datametrex can
assist your organization in social media discovery, Fake News Filters
and BOT detection please go to:
Datametrex AI Limited is a technology focused company with exposure
to Artificial Intelligence and Machine Learning through its wholly owned
subsidiary, Nexalogy (www.nexalogy.com).
For further information, please contact:
Jeff Stevens – President Phone: (416) 482-3282 Email: [email protected]
Forward-Looking Statements
This news release contains “forward-looking information†within
the meaning of applicable securities laws. All statements contained
herein that are not clearly historical in nature may constitute
forward-looking information. In some cases, forward-looking information
can be identified by words or phrases such as “mayâ€, “willâ€, “expectâ€,
“likelyâ€, “shouldâ€, “wouldâ€, “planâ€, “anticipateâ€, “intendâ€,
“potentialâ€, “proposedâ€, “estimateâ€, “believe†or the negative of these
terms, or other similar words, expressions and grammatical variations
thereof, or statements that certain events or conditions “may†or “willâ€
happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors,
uncertainties and potential events carefully and not to put undue
reliance on forward-looking information. The forward-looking information
contained herein is made as of the date of this press release and is
based on the beliefs, estimates, expectations and opinions of management
on the date such forward-looking information is made. The Company
undertakes no obligation to update or revise any forward-looking
information, whether as a result of new information, estimates or
opinions, future events or results or otherwise or to explain any
material difference between subsequent actual events and such
forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 4:30 PM on Wednesday, November 13th, 2019
Why Empower Clinics?
A leading owner/operator of physician staffed health and pain management clinics.
Patient database of over 165,000 patients
Platform generating $4MM USD in revenue annually (2019)
Q3 2019 preliminary unaudited revenue saw a year over year growth of approximately 138%
Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
Launching CBD extraction facility
First extraction system capacity = 6,000 Kg per year.
CBD based products are poised to be a $20B global industry by 2022
Medical cannabis is poised to be a $100B global industry by 2025
The Team
The Products
Commenced selling its proprietary line of CBD-based products called SOLLIEVO
Empower’s patient base and customers are
expected to benefit from access to high margin derivative products,
including CBD lotion, tinctures, spectrum oils, capsules, lozenges,
patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet
elixir hemp extract drops.
Patients and customers will be able to access Empower’s home delivery and e-commerce platform.
CBD Extraction
Opening first CBD Extraction facility in Portland, OR.
5,000 sq. ft. leased building with first extraction system capable
of producing 20kg per day of 99% spectrum oil, isolate or distillate
Current wholesale pricing is $6,500 USD per kg with annual capacity of 6,000kg an estimated $39MM USD revenue.
Facility can scale to four extraction systems for up to 24,000kg of product and over $150MM USD revenue
FULL DISCLOSURE: Empower Clinics is an advertising client of AGORA Internet Relations Corp.
Tags: Cannabis, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on CLIENT FEATURE: Empower Clinics With 165,000 Patients Already, $CBDT.ca Is Positioned To Become A Medical #Cannabis & #CBD Retail Killer $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 3:21 PM on Wednesday, November 13th, 2019
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
Digital Health Market Value to Reach USD 511 Billion by 2026
Demand for digital health is rising on account of the increasing need to improving workflow efficiency across hospitals and other healthcare organizations
In addition to this, there is mounting pressure from governments to reduce healthcare costs, while at the same time focus on improving quality of patient care
The global digital health market value is expected to reach around USD 511 billion by 2026.
The global digital health market is expected to rise exponentially in
the coming years. The already multi-billion industry is likely to grow
at an accelerated pace, as healthcare sector welcomes digitization.
Factors such as the advent of mobile health, wireless solutions, and
telehealth will foster growth opportunities for the digital health
market.
Rising Adoption of mHealth Technologies to Boost Growth
In the coming years, the digital health market is expected to gain
pace in response to the rising adoption of mHealth technologies. These
are advanced technologies that also help in the self-management of
diabetes and other chronic ailments. Taking cue from this, several
companies are launching innovative technologies to help in the same. For
instance, Glooko was launched specifically to help in the management of
diabetes. Similar apps are now increasingly available across
smartphones, making it easier for the healthcare professionals and
patients alike to keep abreast of the most recent patient information.
Development of these technologies is lauded as they are significantly
helping in disease diagnosis and monitoring. These are a few of the
chief digital health market trends that are likely to enable growth in
the coming years. Bolstering this will be the rising penetration of
smartphones, smart devices, and better internet connectivity around the
world.
Demand for Improving Workflow Efficiency to Boost Uptake in Healthcare Organizations
The demand for digital health is rising on account of the increasing
need to improving workflow efficiency across hospitals and other
healthcare organizations. In addition to this, there is mounting
pressure from governments to reduce healthcare costs, while at the same
time focus on improving quality of patient care. Recent advancements in
the technology showcased the inclusion of mobile, big data, cloud, and
interoperability. Following these developments, a surge in the demand
for EHR is observed, subsequently boosting growth prospects for the
digital health market. In addition to this, an increasing number of
companies are investing in developing innovations in EHR. For instance,
Allscripts launched a mobile first and cloud based EHR, dubbed as
Avenel, in 2018. The system uses machine learning to bring down time
taken for clinical documentation. It works more like an application.
Such developments are expected to bode well for the overall market.
Posted by AGORACOM-JC
at 11:48 AM on Wednesday, November 13th, 2019
Announced the closing by its subsidiary, ZeU Crypto Networks Inc., of a non-brokered private placement offering of 12% capitalized interests unsecured convertible debentures for an aggregate principal amount of CAD $7,824,000
Subscribed in consideration of digital assets, consisting 24,000,000 Kamari, each a “KAM“, at a deemed value of CAD $0.326 each.
Valletta, Malta – November 13, 2019 – St-Georges Eco-Mining Corp. (CNSX:SX.CN)(OTC:SXOOF) (FSE:85G1) is pleased to announce the closing by its subsidiary, ZeU Crypto Networks Inc., of a non-brokered private placement offering of 12% capitalized interests unsecured convertible debentures for an aggregate principal amount of CAD $7,824,000 subscribed in consideration of digital assets, consisting 24,000,000 Kamari, each a “KAM“, at a deemed value of CAD $0.326 each.
ZeU has also executed a joint venture agreement with Kamari Limited (“Kamari“) of Malta for the joint development and deployment of lotteries and gaming offerings in Africa (the “JV Co.“).
Under the terms of the JV, both parties agreed to invest up to Euro
50,000, ZeU agreed, among other things, to grant JV Co. a non-exclusive
licence to its technologies in exchange for a 30% interest in JV Co.,
and Kamari agreed to provide JV Co. with support in accessing online
lottery markets exchange for a 70% interest in JV Co. For more
information on Kamari visit www.kamari.io
The Debenture issued pursuant to the Offering will have a maturity date of May 12, 2022 (the “Maturity Date“), and be convertible into common shares of ZeU (each a “ZeU Share“) at a price (the “Conversion Price“) equal to the greater of: (i) $1.50, and (ii) if the date of any conversion occurs after ZeU completed a transaction (a “Liquidity Event“) pursuant
to which it will become a “reporting issuer” under applicable Canadian
securities laws and the ZeU Shares would be listed and posted for
trading on a recognized exchange, the 10-day volume-weighted average trading price of the ZeU Shares, immediately prior to the applicable conversion date.
Upon the occurrence of a Liquidity
Event, ZeU will be entitled to require the holders of the Convertible
Debentures to convert up to 50% of the principal amount outstanding,
together with any accrued and unpaid interest owing thereon, into ZeU
Shares at the Conversion Price.
ZeU will be entitled to redeem the
Debentures at any time, including on the Maturity Date, in cash, in
digital assets for the pro rata nominal amount of digital assets
subscribed or in ZeU shares at the Conversion Price.
The KAM forming the Consideration
are subject to the following voluntary transfer restrictions: (i) in any
one-month period, transfer, directly or indirectly, is limited to
1/30th of the total number of KAM forming the Consideration; and (ii) in
any given day, any sale on an exchange is limited to 5% of the total
volume of KAM traded, without the prior written consent of Kamari.
The securities issued in connection with the Offering are
subject to the applicable statutory hold period ending March 12, 2020.
Closing of the Offering is subject to receipt of applicable regulatory
approvals, including the approval of the CSE.
ON BEHALF OF THE BOARD OF DIRECTORS
“Frank Dumas”
FRANK DUMAS
DIRECTOR & COO, ST-GEORGES ECO-MINING
PRESIDENT & CEO, ZEU CRYPTO NETWORKS.
The Canadian
Securities Exchange (CSE) has not reviewed and does not accept
responsibility for the adequacy or the accuracy of the contents of this
release.
Posted by AGORACOM-JC
at 10:34 AM on Wednesday, November 13th, 2019
SPONSOR: NORTHBUD (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. Learn More.
—————————–
The CBD Industry Flourishes After Overcoming Certain Legal Barriers
Total sales for the U.S. hemp industry totaled USD 820 Million in 2017
The research also suggests that the industry is expected to grow to USD 1.9 Billion by 2022 and at a CAGR of 14.4% during the 5-year period.
NEW YORK, Nov. 13, 2019 – Humans have been using hemp for centuries prior to its disappearance from the public eye. Decades ago, hemp was predominantly being used to manufacture textiles, paper, construction materials, and fuel. However, now, hemp is most commonly known for being a derivative of the cannabis plant, which has caused it to be classified as a drug under international regulations.
Furthermore, most people associate cannabis with its marijuana
derivative, which imparts cerebral-altering effects on its users.
However, hemp and marijuana are two completely different plants in terms
of their biological makeup. Hemp contains much more CBD, or
cannabidiol, while marijuana contains a significant amount of THC, or
tetrahydrocannabinol. In fact, CBD and THC are just two of at least 113
cannabinoids identified in the cannabis plant. However, THC is one of
the only three cannabinoids scheduled by the UN Convention on
Psychotropic Substances. Originally, the UN listed THC as a Schedule 1
substance in 1971 but reclassified it to Schedule 2 in 1991 after a
recommendation by the World Health Organization (WHO).
However, under the Single Convention on Narcotic Drugs, THC is
classified as both a Schedule 1 and Schedule 4 drug. And while the
debate over legalizing THC is often a tense topic for most countries,
CBD legalization appears to be a more popular direction of discourse. In
recent times, CBD has become widely popular because of the therapeutic
benefits it offers without causing psychoactive effects on the consumer.
Notably, researchers highlighted that CBD can be used to treat minor
conditions such as headaches or even severe symptoms associated with
cancer. Nevertheless, international health agencies have all agreed that
more research is required in order to move forward with approving CBD
as a medicinal treatment.
But regardless, a number of countries such as Canada and
the U.S. already moved to completely legalize the use of CBD. And
according to data compiled by Hemp Business Journal, a division of New
Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million in 2017. The research also suggests that the industry is expected to grow to USD 1.9 Billion by 2022 and at a CAGR of 14.4% during the 5-year period.
In 2017, the U.S. hemp market was primarily driven by hemp-derived
CBD products. At the time, hemp-derived CBD products accounted for 23%
of the total market share, delivering USD 190 Million in
sales. Personal care products accounted for 22% of the market share,
narrowly lagging behind hemp-derived CBD products. However, by 2022,
Hemp Business Journal expects the hemp-derived CBD market to takeoff.
The hemp-derived CBD sector is forecast to deliver USD 646 Million
in sales. Furthermore, the research suggests that the personal care
products segment is expected to witness its market share diminishes as
industrial applications fill the gap. And as legal barriers are removed
and consumer education continues to spread, the hemp industry is
positioned to witness exponential growth.
Furthermore, many researchers are actively pushing legislators and
lawmakers to reconsider the scheduling of cannabis because of rich
therapeutic benefits. For instance, researchers from the University of Minnesota’s
(U of M) College of Biological Sciences and College of Food,
Agricultural, and Natural Resource Sciences are one of a handful of
groups that are federally authorized to study cannabis. The researchers
have argued they have “indisputable evidence” that hemp and marijuana
should be separated, according to Mercola. “It’s a plant of major
economic importance that is very poorly understood scientifically… With
this study, we have indisputable evidence for a genetic basis of
differences among cannabis varieties, further challenging the position
that all cannabis should be regulated as a drug,” said George Weiblen,
a professor with a joint appointment in the U of M’s College of
Biological Sciences and College of Food, Agricultural and Natural
Resource Sciences.
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – The #CBD Industry Flourishes After Overcoming Certain Legal Barriers $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 9:50 AM on Wednesday, November 13th, 2019
SPONSOR:ThreeD Capital Inc. (IDK:CSE)
Led by legendary financier, Sheldon Inwentash, ThreeD is a
Canadian-based venture capital firm that only invests in best of breed
small-cap companies which are both defensible and mass scalable. More
than just lip service, Inwentash has financed many of Canada’s biggest
small-cap exits. Click Here For More Information.
Canada’s Largest Bank Mulls Crypto Exchange After Bitcoin Ban
A Canadian bank, which banned its clients from buying Bitcoin (BTC), could now become the first in the country to launch a cryptocurrency exchange.Â
As innovation economy news outlet The Logic reported on Nov. 11, the Royal Bank of Canada (RBC) is now rumored to be considering the plans.
A Canadian bank, which banned its clients from buying Bitcoin (BTC), could now become the first in the country to launch a cryptocurrency exchange.
As innovation economy news outlet The Logic reported on Nov. 11, the Royal Bank of Canada (RBC) is now rumored to be considering the plans.
RBC reportedly planning multifunctional exchange
RBC is the largest bank in Canada by market capitalization, with $661 billion CAD ($499 billion) in assets under management.
According to The Logic, the bank is entertaining the possibility for
the exchange to function both for investments and allowing clients to
make purchases online and in brick-and-mortar stores.
The news follows a previous report that Canada’s central bank wanted to use digital currency in order to better track consumer spending habits.
“The trading platform would facilitate buying and selling of individual digital coins, including Bitcoin and Ether (ETH), as well as the transfer of funds combining different types of cryptocurrencies,†the publication summarized.
Bitcoin purchases “not allowedâ€
While little detailed information is currently available, the move
would run conspicuously in contrast to RBC’s current modus operandi on
cryptocurrencies. Last year, the bank abruptly banned clients purchasing
Bitcoin or altcoins with credit and debit cards.
“Effective immediately, RBC will no longer be allowing the use of RBC
credit cards for transactions involving cryptocurrency. We regret any
inconvenience this may cause,†a notice stated at the time.
Nonetheless, attention has since focused on how authorities will handle the fallout from QuadrigaCX,
a local cryptocurrency exchange that imploded in late 2018. While
recovery of lost funds is ongoing, users lost a total of around $190
million in deposits.
